Stockscreener 앱 받기
3.805
1.47%
0.065
전일 마감가:
$3.74
열려 있는:
$3.69
하루 거래량:
911.38K
Relative Volume:
0.57
시가총액:
$525.47M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-10.87
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
-7.44%
1개월 성능:
+2.57%
6개월 성능:
+100.79%
1년 성능:
+123.24%
1일 변동 폭
$3.665
$3.89
1주일 범위
$3.63
$4.08
52주 변동 폭
$1.27
$4.86
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.80 | 641.68M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.02 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.23 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.09 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.63 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.03 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Therapeutics to present data on cancer bispecific antibody - Investing.com
Compass Therapeutics Announces Preclinical Success of CTX-10726 in Targeting Tumor Angiogenesis and Immune Suppression - Quiver Quantitative
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - Stock Titan
Can Compass Therapeutics Inc. recover in the next quarterJuly 2025 Movers & Smart Allocation Stock Reports - newser.com
Will Compass Therapeutics Inc. stock outperform growth indexesJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
How to interpret RSI for Compass Therapeutics Inc. stockGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
Compass Therapeutics to Participate in Upcoming November Investor Events - Yahoo Finance
How Compass Therapeutics Inc. stock performs in weak economyJuly 2025 Fed Impact & Community Shared Stock Ideas - newser.com
Institutional investors in Compass Therapeutics, Inc. (NASDAQ:CMPX) lost 9.0% last week but have reaped the benefits of longer-term growth - Yahoo Finance
Why Compass Therapeutics Inc. stock is seen as undervaluedQuarterly Portfolio Review & Free Low Drawdown Momentum Trade Ideas - newser.com
How Compass Therapeutics Inc. stock performs in stagflationTrade Risk Assessment & Long Hold Capital Preservation Plans - newser.com
Is Compass Therapeutics Inc. stock recession proof2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Will Compass Therapeutics Inc. stock split attract more investorsMarket Risk Summary & Safe Swing Trade Setup Alerts - newser.com
How Compass Therapeutics Inc. stock trades before earningsJuly 2025 Breakouts & Reliable Trade Execution Plans - newser.com
Piper Sandler Remains Bullish on Compass Therapeutics (CMPX) - Insider Monkey
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
How to track smart money flows in Compass Therapeutics Inc.Quarterly Investment Review & Weekly High Potential Alerts - newser.com
Compass Therapeutics’ Phase 1 Study of CTX-8371: A Potential Game-Changer in Cancer Treatment - TipRanks
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.71%
0.18%
자본화:
|
볼륨(24시간):